UHealth - University of Miami Health System

E-mail a Friend


Alan Pollack, M.D., Ph.D.

General Information

Alan  Pollack, M.D., Ph.D.

Appointments

Call 305-243-4000 or request an appointment online

Specialties

  • Radiation Oncology

Languages

English

Clinical Areas

 I specialize clinically in: GU Malignancies (Prostate, Bladder and Testicular cancers) and Sarcomas.

Certifications

  • American Board of Radiology-Radiation Oncology

Roles

  • Professor and Chairman of Radiation Oncology

Research Interests

My research interests are: Radiation fractionation, gene and small molecule therapy to enhance the response of prostate tumor cells to radiation and/or androgen deprivation, and biomarkers to predict response and determine the most appropriate treatment.

My clinical research has focused on prostate and bladder cancers. I am the principal Investigator on a large Phase III prostate cancer randomized trial through the Radiation Therapy Oncology Group (RTOG protocol 0534). This is a post-prostatectomy trial testing the benefits of treating the pelvic lymph nodes and the concurrent use of androgen deprivation with radiation.  I am the co-PI on a national bladder cancer trial through the RTOG testing the use of Herceptin in her-2 expressing muscle-invasive bladder tumors (RTOG protocol 0524). Also, I am developing a new trial at the University of Miami designed to target areas of bulky tumor in men with prostate cancer using dynamic contrast enhanced MR imaging. 

My laboratory research has involved primarily the exploration of potential biomarkers and the addition of targeted therapy (gene and small molecule) to radiotherapy and androgen deprivation therapy. Through the RTOG translational research program a number of potential biomarkers for prostate cancer have been investigated using immunohistochemical staining and analysis (image and manual quantification of biomarker expression). The targeted therapy studies have included preclinical investigations of a number of agents, such as adenoviral-p53, adenoviral-E2F1, antisense-MDM2, antisense-PKA and antisense-bcl-2 in mouse models. The effects of these agents on prostate cancer cell survival in vitro and tumor growth in vivo are being examined.

Publications

  • For more information about Dr. Pollack see CV

Awards

Best Doctors in America
Tops Doctors for Cancer
Top Docs 2002-2008, May issues Philadelphia Magazine
American Cancer Society Career Development Award
Radiology Society of North America Fellowship
The Thomas Brown McClelland Trust Scholarship, Rotary Club of Miami
University of Miami School of Medicine Surgical Scholarship Fund Fellowship

Education

1987 M.D.
University of Miami
1979 Ph.D.
University of Miami
1974 B.S.
University of Florida

CV

E-mail a Friend